A new histone deacetylase inhibitor, MHY219, inhibits the migration of human prostate cancer cells via HDAC1

Biomolecules and Therapeutics

Volumn 23, Issue 5, 2015, Pages 434-441

  De, Umasankar ^a   Kundu, Soma ^b   Patra, Nabanita ^b   Ahn, Mee Young ^c   Ahn, Ji Hae ^a   Son, Ji Yeon ^a   Yoon, Jung Hyun ^b   Moon, Hyung Ryoung ^b   Lee, Byung Mu ^a   Kim, Hyung Sik ^a  

^a Sungkyunkwan University   (South Korea)

^b Pusan National University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

HDAC inhibitor; MHY219; Migration; MMPs; Prostate cancer

Indexed keywords

5 HYDROXY 7 (OXIRAN 2 YLMETHOXY) 2 PHENYL 4H CHROMEN 4 ONE; ANTINEOPLASTIC AGENT; GELATINASE A; HISTONE DEACETYLASE 1; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CELLS BY BODY ANATOMY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; MALE; MIGRATION INHIBITION; MOLECULAR DYNAMICS; PROSTATE CANCER CELL LINE;

EID: 84940387093     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.026     Document Type: Article

References (30)

1. Abbas, A. and Gupta, S. (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3, 300-309.
2. Ahn, M. Y., Kang, D. O., Na, Y. J., Yoon, S., Choi, W. S., Kang, K. W., Chung, H. Y., Jung, J. H., Min, D. S. and Kim, H. S. (2012) Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 325, 189-199.
3. Catalona, W. J. (1994) Management of cancer of the prostate. N. Engl. J. Med. 331, 996-1004.
4. Chambers, A. F. and Matrisian, L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270.
5. Chiu, H. W., Yeh, Y. L., Wang, Y. C., Huang, W. J., Chen, Y. A., Chiou, Y. S., Ho, S. Y., Lin, P. and Wang, Y. J. (2013) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One 8, e76340.
6. Duffy, M. J, Maguire, T. M., Hill, A., McDermott, E. and O'Higgins, N. (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252-257.
7. Emanuele, S., Lauricella, M. and Tesoriere, G. (2008) Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int. J. Oncol. 33, 637-646.
8. Fulda, S. (2008) Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 8, 132-140.
9. Glozak, M. A. and Seto, E. (2007) Histone deacetylases and cancer. Oncogene 26, 5420-5432.
10. Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E. and Robson, C. N. (2004a) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177-189.
11. Halkidou, K., Cook, S., Leung, H.Y., Neal, D. E. and Robson, C. N. (2004b) Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur. Urol. 45, 382-389.
12. Jung, K. W., Won, Y. J, Kong, H. J., Oh, C. M., Seo, H. G. and Lee, J. S. (2013) Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res. Treat. 45, 15-21.
13. Kim, H. J., Park, M. K., Kim, S. Y. and Lee, C. H. (2014) Novel suppressive effects of ketotifen on migration and invasion of MDA-MB-231 and HT-1080 cancer cells. Biomol. Ther. 22, 540-546.
14. Kim, M. S., Son, M. W., Kim, W. B., Park, Y. I. and Moon, A. (2000) Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 157, 23-30.
15. Laurenzana, A., Balliu, M., Cellai, C., Romanelli, M. N. and Paoletti, F. (2013) Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One 8, e58267.
16. LeRoith, D., Baserga, R., Helman, L., Roberts, C.T.Jr. (1995) Insulinlike growth factors and cancer. Ann. Intern. Med. 122, 54-59.
17. Levy, D. E., Lapierre, F., Liang, W., Ye, W., Lange, C. W., Li, X., Grobelny, D., Casabonne, M., Tyrrell, D., Holme, K., Nadzan, A. and Galardy, R. E. (1998) Matrix metalloproteinase inhibitors: a structure-activity study. J. Med. Chem. 41,199-223.
18. Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
19. Liotta, L. A. (1986) Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46, 1-7.
20. Min, K. N., Joung, K. E., Kim, D. K. and Sheen, Y. Y. (2012) Anti-cancer effect of IN-2001 in MDA-MB-231 human breast cancer. Biomol. Ther. 20, 313-319.
21. Pacheco, M. M., Mourão, M., Mantovani, E. B., Nishimoto, I. N. and Brentani, M. M. (1998) Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin. Exp. Metastasis 16, 577-585.
22. Patra, N., De, U., Kim, T. H., Lee, Y. J., Ahn, M. Y., Kim, N. D., Yoon, J. H., Choi, W. S., Moon, H. R., Lee, B. M. and Kim, H.S. (2013) A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Biomed. Pharmacother. 67, 407-415
23. Prins, G. S. (2008) Endocrine disruptors and prostate cancer risk. Endocr. Relat. Cancer 15, 649-656.
24. Pulukuri, S. M. and Rao, J. S. (2008) Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int. J. Oncol. 32, 757-765.
25. Robbins, A. R., Jablonski, S. A., Yen, T. J., Yoda, K., Robey, R., Bates, S. E. and Sackett, D. L. (2005) Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4, 717-726.
26. Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M. and Kurdistani, S. K. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266.
27. Seo, J., Min, S. K., Park, H. R., Kim, D. H., Kwon, M. J., Kim, L. S. and Ju, Y. S. (2014) Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J. Breast Cancer 17, 323-331.
28. Weichert, W., Röske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M. and Kristiansen, G. (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98, 604-610.
29. Zhang, L., Liu, N., Xie, S., He, X., Zhou, J., Liu, M., Li, D. (2014) HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol. Ther. 15, 1561-1570
30. Zhao, W., Han, H. B. and Zhang, Z. Q. (2011) Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation. Int. J. Biochem. Cell Biol. 43, 1459-1468.